Wet age-related macular degeneration research hub
3 indexed studies · 0 currently recruiting
- recruitingPhase I
An early-stage study to see if U8:ranibizumab eye drops are safe, well-tolerated, and effective for patients with a specific eye condition called choroidal neovascularisation
This study tests new eye drops for wet AMD, a condition causing central vision loss. It checks if the drops are safe, work well, and are better than injections. We're looking for adults aged 60+ with wet AMD to join.
United Kingdom · England - active not recruitingPHASE3
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
This study, called LUCIA, is looking at a new treatment called EYP-1901 for wet age-related macular degeneration (wAMD). Researchers want to see if EYP-1901 is as effective as a standard treatment, aflibercept, over two years for improving or maintaining eyesight.
United States · Brazil · Czechia - active not recruitingPHASE3
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
This study is testing a new, one-time gene therapy called ABBV-RGX-314 for wet age-related macular degeneration (wet AMD). It aims to see if this treatment can improve vision and reduce the need for frequent eye injections, compared to the standard treatment, aflibercept (EYLEA®).
United States · Canada · France